LBA98 Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype
M. Brahmi, Camille Schiffler, M. Toulmonde, Thibaud Valentin, Agnès Ducoulombier, Christophe Perrin, N. Penel, Isabelle Desmoulins, C. Tlemsani, François Bertucci, Justine Gantzer, Nicolás Isambert, L. Chaigneau, Isabelle Laure Ray-Coquard, Séverine Metzger, David Pérol, Jean Yves Blay, A. Dufresne (2025). LBA98 Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.09.115.
